Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
13.49
+0.63 (4.90%)
Apr 29, 2026, 12:31 PM EDT - Market open
Company Description
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1β-based treatments for immune-mediated inflammatory diseases in the Unites States.
Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1β, which is in phase 2 clinical trial to treat inflammatory diseases.
The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021.
Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
Avalo Therapeutics, Inc.
| Country | United States |
| Founded | 2011 |
| IPO Date | Oct 15, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Garry Neil |
Contact Details
Address: 1500 Liberty Ridge Drive, Suite 321 Wayne, Pennsylvania 19087 United States | |
| Phone | 410 522 8707 |
| Website | avalotx.com |
Stock Details
| Ticker Symbol | AVTX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001534120 |
| CUSIP Number | 05338F108 |
| ISIN Number | US05338F3064 |
| Employer ID | 45-0705648 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Garry A. Neil M.D. | President, Chief Executive Officer and Director |
| Dr. Mittie Doyle FACR, M.D. | Chief Medical Officer |
| Taylor Boyd | Chief Business Officer |
| Dr. Solomon H. Snyder M.D. | Founder and Chairman of Scientific Advisory Board |
| Dr. Barbara S. Slusher Ph.D. | Founder and Member of Scientific Advisory Board |
| Christopher Ryan Sullivan CPA | Chief Financial Officer and Head of Investor relations |
| Paul C. Varki J.D., M.P.H | Chief Legal Officer |
| Ashley Ivanowicz | Senior Vice President of Human Resources |
| Dr. Dino C. Miano Ph.D. | Senior Vice President of CMC and Technical Operations |
| Jennifer Riley | Chief Strategy Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2026 | 8-K | Current Report |
| Apr 10, 2026 | ARS | Filing |
| Apr 10, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 10, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 6, 2026 | 144 | Filing |
| Apr 1, 2026 | 144 | Filing |
| Apr 1, 2026 | SCHEDULE 13G | Filing |
| Mar 27, 2026 | 8-K | Current Report |
| Mar 23, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 23, 2026 | 10-K | Annual Report |